Cure of Multidrug-Resistant Human B-Cell Lymphoma Xenografts by Combinations of Anti-B4-Blocked Ricin and Chemotherapeutic Drugs

By Changnian Liu, John M. Lambert, Beverly A. Teicher, Walter A. Blättler, and Rosemary O’Connor

The CD-19-directed immunotoxin anti-B4-blocked ricin (anti-B4-bR) is currently in clinical trials for the treatment of B-cell malignancies. To explore the potential of using anti-B4-bR with chemotherapy protocols we tested the in vivo efficacy of the immunotoxin in combination with two multidrug chemotherapeutic regimens in severe combined immunodeficient (SCID) mice bearing disseminated tumors of the multidrug-resistant human B-cell lymphoma Namalwa/mdr-1. In cytotoxicity studies in vitro, combinations of the immunotoxin with cisplatin produced supra-additive killing effects on both Namalwa and Namalwa/mdr-1 cells, whereas anti-B4-bR combined with 4-hydroperoxy-cyclophosphamide caused additive killing of both cell lines. In vivo cyclophosphamide, cisplatin, vincristine, doxorubicin, and etoposide as single agents, were effective in prolonging the survival of SCID mice burdened with the Namalwa tumor, whereas only cyclophosphamide and cisplatin were effective on Namalwa/mdr-1 tumors. Treatment of Namalwa/mdr-1-bearing mice with anti-B4-bR alone or with the drug combination CHOE (consisting of cyclophosphamide, vincristine, doxorubicin, and etoposide) alone increased the lifespan of the tumor-burdened mice by 58% and 73%, respectively. However, treatment with five daily bolus intravenous injections of anti-B4-bR followed by CHOE increased the lifespan by 173%, and 20% of the mice were cured. The drug combination CCE (cyclophosphamide, cisplatin, and etoposide) alone could increase the lifespan of the Namalwa/mdr-1 tumor-burdened mice by 129% compared with untreated controls. Combination therapy with anti-B4-bR and CCE produced long-term cures in 50% of the tumor-burdened mice. These results suggest that anti-B4-bR in combination with current multidrug regimens may constitute a highly efficacious modality for the treatment of drug-resistant B-cell malignancies.

© 1996 by The American Society of Hematology.

MATERIALS AND METHODS

Immunotoxin and drugs. Anti-B4-bR was manufactured by ImmunoGen, Inc (Cambridge, MA) as described previously.12-13 Vin-cristine was from Eli Lilly Co (Indianapolis, IN); doxorubicin from galactose-binding sites blocked by covalently linked affinity ligands to minimize nonspecific toxicity.12-13 The CD19 antigen is expressed on normal and neoplastic B-cells, is B-lineage restricted, and is detected early in B-cell ontogeny.14-15 Anti-B4-bR has shown cytotoxic potency, selectivity, and specificity in vitro.12-13 and has shown antitumor effects in SCID mouse models of human CD19+ B-cell neoplasms.15-17 Phase I dose escalation trials have shown safety and hinted at therapeutic efficacy for patients with relapsed and refractory B-cell neoplasms.18-20

To develop a rationale for combining anti-B4-bR with chemotherapeutic drug regimens we studied the interaction of the immunotoxin with doxorubicin and etoposide on the drug-sensitive Burkitt’s lymphoma cell line Namalwa and the multidrug-resistant cell line Namalwa/mdr-1.21 Anti-B4-bR showed synergistic killing with both of these drugs on the drug-sensitive and drug-resistant Namalwa cells in vitro. Treatment of the Namalwa/mdr-1 xenografts in vivo with anti-B4-bR could completely reverse the drug-resistant phenotype and render the tumors as sensitive to either doxorubicin or etoposide as the Namalwa tumors.21 In this study these observations were extended to show that anti-B4-bR synergizes with the alkylating agents 4-hydroperoxy-cyclophosphamide (4-HC) and cisplatin in vitro on both Namalwa and Namalwa/mdr-1 cells. Furthermore, it was found that anti-B4-bR could cure the Namalwa/mdr-1 tumor-bearing animals when used in combination with multidrug regimens. The two drug regimens, CHOE and CCE, are experimental mimics of the clinically used regimens CHOE22,23 (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) and ICE24-26 (ifosfamide, carboplatin, and etoposide) for treatment of recurrent or refractory non-Hodgkin’s lymphoma.

From ImmunoGen, Inc. Cambridge, MA; and Dana-Farber Cancer Institute, Boston, MA.
Submitted October 17, 1995; accepted December 21, 1995.
Address reprint requests to Changnian Liu, PhD, ImmunoGen, Inc, 148 Sidney St, Cambridge, MA 02139.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1996 by The American Society of Hematology.

From www.bloodjournal.org by guest on July 5, 2017. For personal use only.
Cetus Corporation (Emeryville, CA); etoposide, cisplatin, and cyclophosphamide from Bristol Laboratories (Evansville, IN); and 4-HC, which was used as an activated analog of cyclophosphamide for in vitro studies, was purchased from Nova Pharmaceutical Corporation (Baltimore, MD).

**Cells.** The Namalwa/mdr-1 cell line was obtained through transfection of a human mdr-1 complementary DNA into the drug-sensitive Burkitt's lymphoma cell line Namalwa (ATCC CRL 1432) as described previously. The Namalwa/mdr-1 cell line was established from a clone growing in 50 nmol/L vincristine and that displayed cross-resistance to doxorubicin and etoposide.

**Cytotoxicity assay and data analysis.** Tumor cell lines were maintained as described previously. Both the drug-sensitive (1.7 × 10^6 cells/well) and drug-resistant cells (1.2 × 10^6 cells/well) were incubated in the presence of various concentrations of anti-B4-bR, vincristine, doxorubicin, etoposide, cisplatin, or 4-HC for 72 hours. Surviving cells were then assayed by exposure to [3H]-thymidine (1 μCi/well) for 18 hours followed by counting the radioactivity incorporated into precipitated polymers. Cultures not exposed to drugs served as controls. Data were calculated as average counts per minute (cpm) from three experiments, each performed in 96-well plates using triplicate wells for each data point. Dose response curves were generated based on expressing cpm from treated cells as a fraction of cpm from untreated cells. IC_{50} values (defined as the concentration of drug that reduced [3H]dT by 63%) were determined graphically from relative survival curves. The in vitro data were analyzed using an adaptation of isobologram methodology used in the case where one agent is held constant as described previously. Envelopes of additivity are derived from mode I additivity which accounts for potency differences between the two agents and mode II additivity, which is derived from the linear isoeffect relationship. Combinations producing an effect within the envelope boundaries of mode I and mode II are considered to be additive; those displaced to the left are greater than additive (ie, supra-additive), whereas those displaced to the right are less than additive (ie, subadditive).

**Animals and tumor models.** Female CB-17 SCID mice were obtained from Massachusetts General Hospital (Boston, MA) and were quarantined for at least 1 week. Animals were housed on a 12-hour light-dark cycle with food and water available ad libitum. Cages, bedding, food, and water were sterilized. Water was acidified with 1N hydrochloric acid to pH 2.4 to suppress growth of Pseudomonas. When the mice were 6 to 7 weeks of age, a suspension (0.2 nL) of Namalwa/mdr-1 or Namalwa cells (4 × 10^6 cells) was injected into a tail vein of the animals. This procedure resulted in a 100% tumor take with untreated or PBS-treated animals dying over approximately a 5 day range with a median survival time (MST) of about 25 days after tumor inoculation. Necropsy of tumor-bearing animals showed that the tumors have tropism for the ovaries, leptomeninges of the brain, bone marrow (BM) of the vertebra, dura mater of the spinal cord, and the muscles surrounding the spinal column.

**Treatment techniques.** Anti-B4-bR was diluted appropriately with phosphate-buffered saline (PBS), pH 7.4, containing 0.1% human serum albumin (HSA), and injected into a tail vein of tumor bearing animals. The chemotherapeutic drugs vincristine, doxorubicin, etoposide, cyclophosphamide or cisplatin were administered intravenously (I.v.). Preliminary studies indicated that sequential treatments with anti-B4-bR and chemotherapeutic drugs were more effective than concurrent administration. Therefore, the combination therapies with anti-B4-bR and the multidrug regimens were conducted by treatment with the immunotoxin for 5 days starting on day 7 after tumor inoculation, followed by the multidrug regimens. To avoid excessive toxicity, the total doses of each agent were administered at about 45% to 65% of their maximum tolerated doses (MTDs) and the administration schedule altered so that the mice did not decrease in body weight more than 20% during the therapy. The MTD was defined as the maximum dose that could be administered to tumor-bearing mice without resulting in drug-related death. Optimal doses for the multidrug regimens were developed which gave maximal therapeutic benefit without deaths in the treated groups of mice. Control animals received no treatment, as we have observed previously that treatment with vehicle solution (PBS containing 0.1% HSA) did not alter the survival of the tumor-bearing mice. A group receiving anti-B4-bR alone, as well as a group receiving the multidrug regimen alone at their respective optimal treatment schedules were included in each experiment as positive controls.

**Endpoints and data analysis.** Each group contained 8 to 10 tumor-bearing animals. The endpoint for this study was animal survival. Animals were checked daily and animals that showed deteriorating and moribund condition were euthanized with CO₂. The survival of all mice was followed and an MST calculated for each group. The increase in life-span (ILS) was calculated by dividing the MST of a treatment group by the MST of the control group and is expressed as the percent increase over the life-span of the control animals. Statistical analysis was performed by the log-rank test and the Wilcoxon test at the 5% significance level.

**RESULTS**

**Combinations of anti-B4-bR and cisplatin or 4-HC on Namalwa and Namalwa/mdr-1 cells.** The sensitivity of Namalwa and Namalwa/mdr-1 to anti-B4-bR and chemotherapeutic drugs in vitro has been previously reported. Namalwa cells were slightly more resistant than Namalwa-mdr-1 cells to cisplatin with IC_{50} values of 250 nmol/L and 170 nmol/L, respectively, whereas both cell lines had an IC_{50} of 1 μmol/L towards 4-HC. Namalwa cells were also slightly more resistant than Namalwa/mdr-1 cells to anti-B4-bR with IC_{50} values of 8 pmol/L and 4 pmol/L, respectively. Namalwa-mdr-1 cells were approximately sixfold more resistant to doxorubicin and etoposide, and 40-fold more resistant to vincristine, showing a functional MDR phenotype.

To study the cytotoxic effects of anti-B4-bR combined with cisplatin, Namalwa and Namalwa/mdr-1 cells were incubated with anti-B4-bR at concentrations of 10 pmol/L or 20 pmol/L and treated simultaneously with cisplatin at concentrations ranging from 0.1 to 1.0 μmol/L in the case of Namalwa cells and 0.1 to 0.5 μmol/L in the case of Namalwa-mdr-1 cells. The cytotoxicity was measured by [3H]-dT incorporation assays and the killing curves were subjected to isobologram analysis. The resultant isobolograms with the calculated envelopes of additivity are shown in Fig 1A (Namalwa) and Fig 1B (Namalwa/mdr-1). They indicate additive killing with the lower concentration of anti-B4-bR (10 pmol/L) for each cell line. At the higher concentration of anti-B4-bR (20 pmol/L), the killing curves lie significantly outside the envelope of additivity in the area of supra-additivity.

The cytotoxic effects of combinations of anti-B4-bR and 4-HC were assessed in a similar way. Namalwa and Namalwa-mdr-1 cells were incubated with anti-B4-bR at concentrations of 10 pmol/L and 20 pmol/L. Each immunotoxin level was combined with 4-HC concentrations ranging from 0.5 to 3 μmol/L or 0.5 to 2 μmol/L for Namalwa and Namalwa/mdr-1 cells, respectively. Isobolograms obtained are...
Fig 1. Isobolograms for combination of anti-B4-bR with cisplatin. Namalwa cells (A) and Namalwa/mdr-1 cells (B) were incubated with the indicated concentrations of Anti-B4-bR and cisplatin for 72 hours and then pulsed with [³²P]dT for 18 hours. Data are presented as the mean and standard deviation of three experiments, in which the cpm incorporated into treated cells is expressed as a fraction of cpm incorporated into control cells. (–[]–), the killing curves for cisplatin alone; (–Δ–), killing curves for anti-B4-bR combined with cisplatin; and (–––), boundaries of the envelopes of additivity for the combination treatments.

Fig 2. Isobolograms for combination of anti-B4-bR with 4-HC. Namalwa cells (A) and Namalwa/mdr-1 cells (B) were incubated with the indicated concentrations of Anti-B4-bR and 4-HC for 72 hours and then pulsed with [³²P]dT for 18 hours. Data are presented as the mean and standard deviation of three experiments, in which the CPM incorporated into treated cells is expressed as a fraction of CPM incorporated into control cells. (–[]–), the killing curves for 4-HC alone; (–Δ–), killing curves for anti-B4-bR combined with 4-HC; (–––), boundaries of the envelopes of additivity for the combination treatments.

shown in Fig 2A (Namalwa) and Fig 2B (Namalwa/mdr-1). The killing curves for anti-B4-bR at both 10 pmol/L and 20 pmol/L concentrations show additive killing towards Namalwa cells. Namalwa/mdr-1 cells show additive killing at 10 pmol/L and supra-additive killing at 20 pmol/L Anti-B4-bR.

Anti-B4-bR and chemotherapy in treatment of the MDR tumor Namalwa/mdr-1. The finding of additive or synergistic killing with anti-B4-bR and cisplatin or 4-HC on Namalwa/mdr-1 cells, coupled with our previously reported synergy between Anti-B4-bR and doxorubicin, etoposide, vincristine and vincristine on these cell lines in vitro and in vivo encouraged us to explore the possibility of combining anti-B4-bR with multidrug regimens consisting of both MDR-related drugs and non-MDR-related drugs. In support of these studies, we developed doses and efficacy data for all of the chemotherapeutic drugs as single agents that had to be established for the Namalwa tumor model in SCID mice.

The therapeutic efficacy of anti-B4-bR and the chemotherapeutic drugs cyclophosphamide, cisplatin, vincristine, doxorubicin and etoposide, as single agents in the treatment of Namalwa or Namalwa/mdr-1 xenograft tumors are summarized in Table 1 and Table 2, respectively. All agents at their respective MTD were effective in prolonging survival of the
Namalwa tumor burdened-mice. Administration of anti-B4-βR alone beginning on day 7 after tumor inoculation resulted in an MST of 38 days or an ILS of 65% over the life span of untreated control animals (MST = 23 days). Treatment with cyclophosphamide alone produced an MST of 44 days (ILS = 91%). Vincristine, doxorubicin and etoposide were somewhat less effective: therapy with each of the three drugs as single agents resulted in MST values of 28 days (ILS = 22%), 29 days (ILS = 26%), and 30 days (ILS = 32%), respectively.

Namalwa/mdr-1 tumor-bearing mice treated with five daily bolus iv injections of anti-B4-βR resulted in an MST value of 43 days which, when compared to the control MST of 25 days, corresponds to an ILS of 72% (Table 2). Vincristine, doxorubicin, or etoposide as single agents at their respective MTD did not show significant effects on survival of the Namalwa/mdr-1 tumor-burdened mice. However, treatment with both cyclophosphamide and cisplatin, drugs that are not subject to MDR, were effective in prolonging survival of treated animals with MSTs of 48 days (ILS = 92%) and 32 days (ILS = 28%), respectively. Noteworthy in this study as well as in our previous study is that the Namalwa/mdr-1 tumor is more responsive to anti-B4-βR than the drug-sensitive Namalwa tumor.

**Combination therapies of the MDR tumor Namalwa/mdr-1 with anti-B4-βR and multidrug regimens.** We next explored the possibility of combining anti-B4-βR with multidrug regimens, which would be used in a clinical setting and consist of the drugs used above. Based on the data with reversal of drug resistance in the Namalwa/mdr-1 cells, and because synergy with the alkylating drug 4-HC and cisplatin was observed on both Namalwa and Namalwa/mdr-1 cells, two multidrug regimens, CHOE and CCE were investigated in SCID/Namalwa/mdr-1 model.

In the anti-B4-βR-CHOE study, Namalwa/mdr-1 tumor-bearing mice were treated either with anti-B4-βR alone, with CHOE alone, or with anti-B4-βR plus CHOE (Fig 3). Although treatment with an optimal dose of the multidrug regimen alone or treatment with anti-B4-βR alone (50 μg/kg/d × 5, 67% of the MTD) could significantly increase survival of the tumor-burdened mice (MSTs = 41 and 45 days, respectively, compared to the MST of 26 days for the control group; ILS of 58% and 73%, respectively; P < .001), there were no cures. However, treatment with anti-B4-βR followed by the same doses of CHOE resulted in an MST of 71 days for treated mice (ILS = 173%) and produced long-term cures in 2 of 10 mice (animals survived over 180 days at which time the experiment was terminated, Fig 3). When gross and histopathologic examinations were performed, neither of these mice had any sign of tumor.

An even better result was observed in mice when treatment with anti-B4-βR was combined with the CCE regime (Fig 4). In this study Namalwa/mdr-1 tumor-bearing mice were treated either with anti-B4-βR alone, with the CCE regimen alone, or with anti-B4-βR plus CCE. Treatment with the optimal dose of CCE alone was effective in increasing the MST of the animals from 24 days (control group) to 55 days (ILS = 129%; P < .0005). Anti-B4-βR alone increased the MST to 40 days (ILS = 67%, P < .001). The combination therapy of anti-B4-βR plus CCE was extremely effective.

### Table 1. Anti-B4-βR and Chemotherapy in Treatment of the Drug-Sensitive Namalwa Tumor in a SCID Mouse Model

<table>
<thead>
<tr>
<th>Treatment*</th>
<th>MST1 (days)</th>
<th>ILS (%)</th>
<th>P Value‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated control</td>
<td>23 (20-26)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Anti-B4-βR (75 μg/kg × 5, d7-11)</td>
<td>39 (35-43)</td>
<td>65</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Cyclophosphamide (100 mg/kg × 3, d7, 9, 11)</td>
<td>44 (37-45)</td>
<td>91</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Vincristine (400 μg/kg × 3, d7, 9, 11)</td>
<td>28 (25-29)</td>
<td>22</td>
<td>&lt;.05</td>
</tr>
<tr>
<td>Doxorubicin (3 mg/kg × 3, d7, 11, 15)</td>
<td>29 (23-31)</td>
<td>26</td>
<td>&lt;.05</td>
</tr>
<tr>
<td>Etoposide (15 mg/kg × 3, d7, 9, 11)</td>
<td>30 (21-34)</td>
<td>32</td>
<td>&lt;.01</td>
</tr>
</tbody>
</table>

* Treatment started on day 7 after tumor inoculation. Each group included 8 to 10 tumor-bearing mice.
† The survival range of animals in each group is given in parentheses.
‡ Comparison with control group by Wilcoxon analysis at the 5% significance level.

### Table 2. Anti-B4-βR and Chemotherapy in Treatment of the Drug-Resistant Namalwa/mdr-1 Tumor in a SCID Mouse Model

<table>
<thead>
<tr>
<th>Treatment*</th>
<th>MST1 (days)</th>
<th>ILS (%)</th>
<th>P Value‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated control</td>
<td>25 (24-27)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Anti-B4-βR (75 μg/kg × 5, d7-11)</td>
<td>43 (38-45)</td>
<td>72</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Cyclophosphamide (100 mg/kg × 3, d7, 9, 11)</td>
<td>48 (42-52)</td>
<td>92</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Cisplatin (5 mg/kg × 3, d7, 11, 15)</td>
<td>32 (29-36)</td>
<td>28</td>
<td>&lt;.05</td>
</tr>
<tr>
<td>Vincristine (400 μg/kg × 3, d7, 9, 11)</td>
<td>25 (24-27)</td>
<td>0</td>
<td>NS</td>
</tr>
<tr>
<td>Doxorubicin (3 mg/kg × 3, d7, 11, 15)</td>
<td>26 (23-29)</td>
<td>4</td>
<td>NS</td>
</tr>
<tr>
<td>Etoposide (15 mg/kg × 3, d7, 9, 11)</td>
<td>26 (23-30)</td>
<td>4</td>
<td>NS</td>
</tr>
</tbody>
</table>

Abbreviation: NS; not significant.
* Treatment started at day 7 after tumor inoculation. Each group included 8 to 10 tumor-bearing mice.
† The survival range of animals in each group is given in parentheses.
‡ Comparison with control group by Wilcoxon analysis at the 5% significance level.
and produced long-term cures in 50% of the tumor-burdened mice. Again these mice showed no signs of tumor, confirmed by histopathologic examination on day 180.

**DISCUSSION**

While the testing of immunotoxins alone in the treatment of leukemias and lymphomas is proceeding rapidly in clinical trials, 

the evaluation of immunotoxins in combination with chemotherapy may lead to other promising therapeutic applications. Several investigations 

including our in vitro and in vivo studies have shown synergistic or additive effects of immunotoxins and chemotherapeutic drugs in treatment of certain types of tumors. These studies were focused on drug-sensitive tumors.

In previous studies, we have shown that anti-B4-bR could reverse multidrug resistance of Namalwa/mdr-1 cells to doxorubicin, etoposide, and vincristine in vitro and in vivo. 

In the current study anti-B4-bR produced greater than additive cytotoxicity with the antitumor alkylating drugs 4-HC and cisplatin against both drug-sensitive and drug-resistant tumor cells. The observation that synergistic killing was obtained with these agents on both Namalwa and Namalwa/mdr-1 cells showed that this synergism is independent of the MDR phenotype. This coupled with our previous observation of synergistic cytotoxicity between anti-B4-bR and doxorubicin, etoposide, or vincristine against MDR expressing cells may suggest that anti-B4-bR can synergize with drugs by downregulating several drug-resistance related proteins (such as P-glycoprotein, glutathione synthetase, and glutathione S-transferase) through its action of inhibiting protein synthesis. This indicates that the immunotoxin could be used to good effect when added to chemotherapeutic regimens consisting of both MDR-related and non-MDR-related drugs.

When it was established that anti-B4-bR could interact positively with these different drugs, two multidrug regimens, which are used for the treatment of refractory non-Hodgkin’s lymphoma, were modeled in animals. It is likely that a combination study with the immunotoxin and multidrug regimens would be a more realistic model for the clinical situation and would provide important information for the design of a clinical trial. The combination therapies of anti-B4-bR plus the single agents vincristine, doxorubicin, or etoposide or multidrug regimens (without need to reduce the drug doses) could be tolerated by the tumor-bearing mice. However, in the combination therapies, the intervals of administration of the chemotherapeutic drugs had to be prolonged, because the initial studies showed that using the same treatment schedules as single agent treatment caused unacceptable systemic toxicity as shown by a body weight loss of >20% with several animals dying of toxicity.

An interesting feature of these studies was that although the drug combinations alone without the immunotoxin were effective therapy against the Namalwa/mdr-1 tumor by significantly extending the lifespan of the mice, they could still be improved upon by the immunotoxin anti-B4-bR to bring about cures. This shows how existing drug combinations could be further improved by adding a therapeutic agent such as anti-B4-bR, which does not have overlapping toxicity and is not subject to the same drug-resistant mechanisms as the agents in the existing combinations.

The importance of overcoming the MDR phenotype for a successful cancer treatment has been firmly established.

![Graph](image-url)
Sever alagents, including verapamil, quinidine and amiodarone, rifampicin, chloroquine, progesterone, cyclosporine, tamoxifen, and immunotoxins directed specifically against P-glycoprotein are able to modulate the activity of P-glycoprotein in vitro. However, their clinical utility may be limited because of their other pharmacological activities and their associated toxicities. For example, whereas cyclosporine may have some utility for leukemia, the calcium-channel blocker verapamil has been shown to enhance cytotoxicity by increasing the intracellular accumulation of drugs, but only at concentrations that would result in excessive cellular toxicity. The two antiarrhythmic drugs, quinidine and amiodarone, have also entered clinical trials as chemo sensitizers. Both drugs have also produced a number of adverse clinical side effects.

Anti-B4-bir overcomes this hurdle in the sensitization of the MDR B-cell lymphoma. It is a cytotoxic agent with an activity selective for CD19-expressing cells that can be safely used in humans. A clinical trial is currently underway that takes advantage of the ability of anti-B4-bir to reverse the MDR phenotype and to synergize in vitro and in vivo with non-MDR-related drugs (cyclophosphamide and cisplatin).

ACKNOWLEDGMENT

We are grateful to Susan M. Derr, Cynthia A. Ferris, Christopher Corvi, and Tammy Davis for technical assistance. We thank Dr Roderick T. Bronson (School of Veterinary Medicine, Tufts University, North Grafton, MA) for the histopathologic studies.

REFERENCES

27. Teicher BA, Herman TS, Holden SA, Eder JP: Chemotherapeutic potentiation through interaction at the level of DNA, in Chou...
Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs

C Liu, JM Lambert, BA Teicher, WA Blattler and R O'Connor